Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
CEO Pablo Legorreta stated that "2025 was truly a landmark year for Royalty Pharma as we executed successfully towards our goal to be the premier capital allocator in life sciences with Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights Key growth drivers include increased activity in synthetic royalty transactions, upcoming pivotal clinical and regulatory pipeline readouts, and a focused expansion into markets like China. Royalty Pharma maintains a dynamic allocation strategy, prioritizing high-quality royalty assets and continued share buybacks and dividends, underpinned by recurring portfolio cash flow and cost savings from internalized management. The 2026 guidance incorporates expected impacts from loss of exclusivity for Promacta, biosimilar entry for Tysabri, reduced milestones, and macro risks like the Inflation Reduction Act, wit
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Royalty Pharma Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma reports Q4 results [Seeking Alpha]Seeking Alpha
RPRX
Sec Filings
- 2/11/26 - Form 10-K
- 2/11/26 - Form 8-K
- 2/4/26 - Form 4
- RPRX's page on the SEC website